[1] |
Gogonea V . Structural insights into high density lipoprotein: old models and new facts[J]. Front Pharmacol, 2015, DOI: 10.3389/fphar.2015.00318.
doi: 10.3389/fphar.2020.00857
pmid: 32581810
|
[2] |
王若宁, 刘聪燕, 周建平 , 等. 脂蛋白纳米药物传输系统研究进展[J]. 中国药科大学学报, 2014,45(1):10-16.
|
[3] |
Huang H, Cruz W, Chen J , et al. Learning from biology: synthetic lipoproteins for drug delivery[J]. Wires Nanomed Nanobi, 2015,7(3):298-314.
doi: 10.1002/wnan.2015.7.issue-3
|
[4] |
Brouillette C G, Anantharamaiah G M . Structural models of human apolipoprotein A-I[J]. Biochimica et Biophysica Acta, 1995,1256(2):103-129.
doi: 10.1016/0005-2760(95)00018-8
pmid: 7766689
|
[5] |
Chung B H, Anatharamaiah G M, Brouillette C G , et al. Studies of synthetic peptide analogs of the amphipathic helix. Correlation of structure with function[J]. J Biol Chem, 1985,260(18):10256-10262.
pmid: 4019511
|
[6] |
Datta G, Chaddha M, Hama S , et al. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide[J]. J Lipid Res, 2001,42(7):1096-1104.
pmid: 11441137
|
[7] |
Garber D W, Handattu S P, Datta G , et al. Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins[J]. Curr Pharm Biotechnol, 2006,7(4):235-240.
doi: 10.2174/138920106777950834
pmid: 16918400
|
[8] |
Mishra V K, Palgunachari M N, Segrest J P , et al. Interactions of synthetic peptide analogs of the class A amphipathic helix with lipids: evidence for the snorkel hypojournal[J]. J Biol Chem, 1994,269(10):7185-7191.
pmid: 8125930
|
[9] |
Wang Q, Ma X, Fei H , et al. A peptide-lipid nanoparticle assembly platform with integrated functions for targeted cell delivery[J]. J Mater Chem B, 2016,4(8):1535-1543.
doi: 10.1039/c5tb02783g
pmid: 32263120
|
[10] |
Mader J S, Hoskin D W . Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment[J]. Expert Opin Inv Drug, 2006,15(8):933-946.
doi: 10.1517/13543784.15.8.933
|
[11] |
Gaspar D, Veiga A S, Castanho M A R B. From antimicrobial to anticancer peptides. A review[J]. Front Microbiol, 2013,4:1-16.
doi: 10.3389/fmicb.2013.00001
pmid: 23346082
|
[12] |
Leuschner C, Hansel W . Membrane disrupting lytic peptides for cancer treatments[J]. Curr Pharm Design, 2004,10(19):2299-2310.
doi: 10.2174/1381612043383971
|
[13] |
潘广瑞, 赵晖 . 抗菌肽在肿瘤方面的研究进展[J]. 医学综述, 2015,21(18):3318-3320.
|
[14] |
Mishra V K, Palgunachari M N . Interaction of model class A1, class A2, and class Y amphipathic helical peptides with membranes[J]. Biochemistry, 1996,35(34):11210-11220.
doi: 10.1021/bi960760f
pmid: 8780526
|
[15] |
王克全, 徐寒梅 . 多肽类药物的研究进展[J]. 药学进展, 2015,39(9):642-650.
|
[16] |
Luo H M, Lu L S, Yang F , et al. Nasopharyngeal cancer-specific therapy based on fusion peptide-functionalized lipid nanoparticles[J]. ACS Nano, 2014,8(5):4334-4347.
doi: 10.1021/nn405989n
pmid: 24766601
|
[17] |
Huang C, Jin H L, Qian Y , et al. Hybrid melittin cytolytic peptide-driven ultrasmall lipid nanoparticles block melanoma growth in vivo[J]. ACS Nano, 2013,7(7):5791-5800.
doi: 10.1021/nn400683s
pmid: 23790040
|
[18] |
Ashaben P, Kishore C, Mitra A K . Recent developments in protein and peptide parenteral delivery approaches[J]. Ther Deliv, 2014,5(3):337-365.
doi: 10.4155/tde.14.5
pmid: 24592957
|